Skip to main content
Top
Published in: Tumor Biology 12/2014

01-12-2014 | Research Article

Baicalin, a component of Scutellaria baicalensis, alleviates anorexia and inhibits skeletal muscle atrophy in experimental cancer cachexia

Authors: Bin Li, Lili Wan, Yan Li, Qi Yu, Pengguo Chen, Run Gan, Quanjun Yang, Yonglong Han, Cheng Guo

Published in: Tumor Biology | Issue 12/2014

Login to get access

Abstract

Inflammatory responses are key contributors to cancer cachexia and foster a complex cascade of biological outcomes. Baicalin is a natural compound derived from Scutellaria baicalensis that possesses anti-inflammatory properties in many diseases; therefore, the aim of this study was to verify whether baicalin could ameliorate cachexia in a CT26 adenocarcinoma-induced model. Tumour-bearing and control mice were injected with CT26 adenocarcinoma cells and phosphate-buffered saline (PBS), respectively, and baicalin was administered intraperitoneally for 15 days. During the study, food intake, body weight, major organ weight, gastrocnemius muscle weight, tibialis muscle weight, epididymal fat weight and serum cytokine levels were measured and evaluated. Additionally, the expression of two E3 ubiquitin ligases and NF-κB pathway proteins were detected by Western blot. The total food intake in tumour-bearing mice receiving baicalin from days 1–16, as well as the average food intake on days 10–16, were less than normal but were significantly higher than in vehicle-treated tumour-bearing mice. Loss of tumour-free body mass in vehicle-treated tumour-bearing mice was significantly increased compared with control mice and tumour-bearing mice receiving baicalin. Serum cytokines, including tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6), were lowered in tumour-bearing mice treated with baicalin. Gastrocnemius muscle, epididymal fat, heart and kidney weight were significantly greater in the baicalin treatment groups compared with the vehicle-treated tumour-bearing mice. In addition, the expression of two E3 ubiquitin ligases, as well as phospho-p65, was significantly downregulated, whereas the expression of IκBα was up-regulated in tumour-bearing mice treated with baicalin, as determined by Western blotting. The present study demonstrates that baicalin effectively ameliorates anorexia by inhibiting cytokine expression and prevents skeletal muscle atrophy most likely by inhibiting activation of NF-κB in an experimental cancer cachexia model, suggesting that baicalin represents a promising natural medicine for treating cancer-induced cachexia.
Literature
1.
go back to reference Argilés JM, Anker SD, Evans WJ, et al. Consensus on cachexia definitions. J Am Med Dir Assoc. 2010;11:229–30.CrossRef Argilés JM, Anker SD, Evans WJ, et al. Consensus on cachexia definitions. J Am Med Dir Assoc. 2010;11:229–30.CrossRef
2.
go back to reference Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–95.CrossRef Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–95.CrossRef
3.
go back to reference Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior tochemotherapy in cancer patients. Am J Med. 1980;69:491–7.CrossRef Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior tochemotherapy in cancer patients. Am J Med. 1980;69:491–7.CrossRef
4.
go back to reference Sarhill N, Mahmoud F, Walsh D, et al. Evaluation of nutritional status in advanced metastatic cancer. Support Care Cancer. 2003;11:652–9.CrossRef Sarhill N, Mahmoud F, Walsh D, et al. Evaluation of nutritional status in advanced metastatic cancer. Support Care Cancer. 2003;11:652–9.CrossRef
5.
go back to reference Bruera E, Sweeney C. Cachexia and asthenia in cancer patients. Lancet Oncol. 2000;1:138–47.CrossRef Bruera E, Sweeney C. Cachexia and asthenia in cancer patients. Lancet Oncol. 2000;1:138–47.CrossRef
6.
go back to reference Bruera E. ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ Br Med J. 1997;315:1219.CrossRef Bruera E. ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ Br Med J. 1997;315:1219.CrossRef
7.
go back to reference Skipworth RJ, Stewart GD, Dejong CH, et al. Pathophysiology of cancer cachexia: much more than host–tumour interaction? Clin Nutr. 2007;26:667–76.CrossRef Skipworth RJ, Stewart GD, Dejong CH, et al. Pathophysiology of cancer cachexia: much more than host–tumour interaction? Clin Nutr. 2007;26:667–76.CrossRef
8.
go back to reference Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRef Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRef
9.
10.
go back to reference Argilés JM, Busquets S, López-Soriano FJ. The pivotal role of cytokines in muscle wasting during cancer. Int J Biochem Cell Biol. 2005;37:2036–46.CrossRef Argilés JM, Busquets S, López-Soriano FJ. The pivotal role of cytokines in muscle wasting during cancer. Int J Biochem Cell Biol. 2005;37:2036–46.CrossRef
11.
go back to reference Argilés JM, Busquets S, Moore-Carrasco R, et al. The role of cytokines in cancer cachexia. In Cachexia and wasting: a modern approach. Springer 2006; 467–475. Argilés JM, Busquets S, Moore-Carrasco R, et al. The role of cytokines in cancer cachexia. In Cachexia and wasting: a modern approach. Springer 2006; 467–475.
12.
go back to reference Noguchi Y, Yoshikawa T, Matsumoto A, et al. Are cytokines possible mediators of cancer cachexia? Surg Today. 1996;26:467–75.CrossRef Noguchi Y, Yoshikawa T, Matsumoto A, et al. Are cytokines possible mediators of cancer cachexia? Surg Today. 1996;26:467–75.CrossRef
13.
go back to reference Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16:153–66.CrossRef Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16:153–66.CrossRef
14.
go back to reference Glass DJ. Signaling pathways perturbing muscle mass. Curr Opin Clin Nutr Metab Care. 2010;13:225–9.CrossRef Glass DJ. Signaling pathways perturbing muscle mass. Curr Opin Clin Nutr Metab Care. 2010;13:225–9.CrossRef
15.
go back to reference Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001;294:1704–8.CrossRef Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001;294:1704–8.CrossRef
16.
go back to reference Gomes MD, Lecker SH, Jagoe RT, et al. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci. 2001;98:14440–5.CrossRef Gomes MD, Lecker SH, Jagoe RT, et al. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci. 2001;98:14440–5.CrossRef
17.
go back to reference Cao PR, Kim HJ, Lecker SH. Ubiquitin–protein ligases in muscle wasting. Int J Biochem Cell Biol. 2005;37:2088–97.CrossRef Cao PR, Kim HJ, Lecker SH. Ubiquitin–protein ligases in muscle wasting. Int J Biochem Cell Biol. 2005;37:2088–97.CrossRef
18.
go back to reference Cai DS, Feantz JD, Tawa NE, et al. IKK/NF-B activation causes severe muscle wasting in mice. Cell. 2004;119:285–98.CrossRef Cai DS, Feantz JD, Tawa NE, et al. IKK/NF-B activation causes severe muscle wasting in mice. Cell. 2004;119:285–98.CrossRef
19.
go back to reference Srinivas N. Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives. Xenobiotica. 2010;40:357–67.CrossRef Srinivas N. Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives. Xenobiotica. 2010;40:357–67.CrossRef
20.
go back to reference Hou J, Wang J, Zhang P, et al. Baicalin attenuates proinflammatory cytokine production in oxygen–glucose deprived challenged rat microglial cells by inhibiting TLR4 signaling pathway. Int Immunopharmacol. 2012;14:749–57.CrossRef Hou J, Wang J, Zhang P, et al. Baicalin attenuates proinflammatory cytokine production in oxygen–glucose deprived challenged rat microglial cells by inhibiting TLR4 signaling pathway. Int Immunopharmacol. 2012;14:749–57.CrossRef
21.
go back to reference Zhang N, Van Crombruggen K, Holtappels G, et al. A herbal composition of Scutellaria baicalensis and Eleutherococcus senticosus shows potent anti-inflammatory effects in an ex vivo human mucosal tissue model. Evidence-based complementary and alternative medicine 2012; 2012. Zhang N, Van Crombruggen K, Holtappels G, et al. A herbal composition of Scutellaria baicalensis and Eleutherococcus senticosus shows potent anti-inflammatory effects in an ex vivo human mucosal tissue model. Evidence-based complementary and alternative medicine 2012; 2012.
22.
go back to reference Zhang XP, Feng GH, He JX, et al. Baicalin protects thymus of rats with severe acute pancreatitis. Inflammation. 2010;33:157–65.CrossRef Zhang XP, Feng GH, He JX, et al. Baicalin protects thymus of rats with severe acute pancreatitis. Inflammation. 2010;33:157–65.CrossRef
23.
go back to reference Lim HA, Lee EK, Kim JM, et al. PPARγ activation by baicalin suppresses NF-κB-mediated inflammation in aged rat kidney. Biogerontology. 2012;13:133–45.CrossRef Lim HA, Lee EK, Kim JM, et al. PPARγ activation by baicalin suppresses NF-κB-mediated inflammation in aged rat kidney. Biogerontology. 2012;13:133–45.CrossRef
24.
go back to reference Li L, Bao H, Wu JF, et al. Baicalin is anti-inflammatory in cigarette smoke-induced inflammatory models in vivo and in vitro: a possible role for HDAC2 activity. Int Immunopharmacol. 2012;13:15–22.CrossRef Li L, Bao H, Wu JF, et al. Baicalin is anti-inflammatory in cigarette smoke-induced inflammatory models in vivo and in vitro: a possible role for HDAC2 activity. Int Immunopharmacol. 2012;13:15–22.CrossRef
25.
go back to reference Zeng LX, Dong JC, Yu WQ, et al. Baicalin attenuates inflammation by inhibiting NF-κB activation in cigarette smoke induced inflammatory models. Pulm Pharmacol Ther. 2010;23:411–9.CrossRef Zeng LX, Dong JC, Yu WQ, et al. Baicalin attenuates inflammation by inhibiting NF-κB activation in cigarette smoke induced inflammatory models. Pulm Pharmacol Ther. 2010;23:411–9.CrossRef
26.
go back to reference Tanaka Y, Eda H, Tanaka T, et al. Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res. 1990;50:2290–5.PubMed Tanaka Y, Eda H, Tanaka T, et al. Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res. 1990;50:2290–5.PubMed
27.
go back to reference Murphy KT, Chee A, Trieu J, et al. Importance of functional and metabolic impairments in the characterization of the C-26 murine model of cancer cachexia. Dis Model Mech. 2012;5:533–45.PubMedPubMedCentral Murphy KT, Chee A, Trieu J, et al. Importance of functional and metabolic impairments in the characterization of the C-26 murine model of cancer cachexia. Dis Model Mech. 2012;5:533–45.PubMedPubMedCentral
28.
go back to reference Acharyya S, Butchbach ME, Wang HT, et al. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell. 2005;8:421–32.CrossRef Acharyya S, Butchbach ME, Wang HT, et al. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell. 2005;8:421–32.CrossRef
29.
go back to reference Radbruch L, Elsner F, Trottenberg P, et al. Clinical practice guidelines on cancer cachexia in advanced cancer patients. Aachen, Department of Palliative Medicinen/European Palliative Care Research Collaborative; 2010. Radbruch L, Elsner F, Trottenberg P, et al. Clinical practice guidelines on cancer cachexia in advanced cancer patients. Aachen, Department of Palliative Medicinen/European Palliative Care Research Collaborative; 2010.
30.
go back to reference Yae S, Takahashi F, Yae T, et al. Hochuekkito (TJ-41), A Kampo formula, ameliorates cachexia induced by colon 26 adenocarcinoma in mice. Evidence-based complementary and alternative medicine 2012; 2012: Article ID 976926, 10 pages. Yae S, Takahashi F, Yae T, et al. Hochuekkito (TJ-41), A Kampo formula, ameliorates cachexia induced by colon 26 adenocarcinoma in mice. Evidence-based complementary and alternative medicine 2012; 2012: Article ID 976926, 10 pages.
31.
go back to reference Shadfar S, Couch ME, McKinney KA, et al. Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo. Nutr Cancer. 2011;63:749–62.CrossRef Shadfar S, Couch ME, McKinney KA, et al. Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo. Nutr Cancer. 2011;63:749–62.CrossRef
32.
go back to reference Yang QJ, Wang LL, Zhou ZY, et al. Parthenolide from Parthenium integrifolium reduces tumor burden and alleviate cachexia symptoms in the murine CT-26 model of colorectal carcinoma. Phytomedicine. 2013;20:992–8.CrossRef Yang QJ, Wang LL, Zhou ZY, et al. Parthenolide from Parthenium integrifolium reduces tumor burden and alleviate cachexia symptoms in the murine CT-26 model of colorectal carcinoma. Phytomedicine. 2013;20:992–8.CrossRef
33.
go back to reference Tranmer JE, Heyland D, Dudgeon D, et al. Measuring the symptom experience of seriously ill cancer and noncancer hospitalized patients near the end of life with the memorial symptom assessment scale. J Pain Symptom Manag. 2003;25:420–9.CrossRef Tranmer JE, Heyland D, Dudgeon D, et al. Measuring the symptom experience of seriously ill cancer and noncancer hospitalized patients near the end of life with the memorial symptom assessment scale. J Pain Symptom Manag. 2003;25:420–9.CrossRef
34.
go back to reference Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res. 1999;59:4493–501.PubMed Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res. 1999;59:4493–501.PubMed
35.
go back to reference Fearon KC. The mechanisms and treatment of weight loss in cancer. Proc Nutr Soc. 1992;51:251–65.CrossRef Fearon KC. The mechanisms and treatment of weight loss in cancer. Proc Nutr Soc. 1992;51:251–65.CrossRef
36.
go back to reference Mary G, Rhoads SCK, Fabio P, Doglietto GB, et al. Expression of NF-kappaB and IkappaB proteins in skeletal muscle of gastric cancer patients. Eur J Cancer. 2010;46(1):191–7.CrossRef Mary G, Rhoads SCK, Fabio P, Doglietto GB, et al. Expression of NF-kappaB and IkappaB proteins in skeletal muscle of gastric cancer patients. Eur J Cancer. 2010;46(1):191–7.CrossRef
37.
go back to reference Chen WC, Kuo TH, Tzeng YS, et al. Baicalin induces apoptosis in SW620 human colorectal carcinoma cells in vitro and suppresses tumor growth in vivo. Molecules. 2012;17:3844–57.CrossRef Chen WC, Kuo TH, Tzeng YS, et al. Baicalin induces apoptosis in SW620 human colorectal carcinoma cells in vitro and suppresses tumor growth in vivo. Molecules. 2012;17:3844–57.CrossRef
38.
go back to reference Qiu JZ, Niu XD, Dong J, et al. Baicalin protects mice from staphylococcus aureus pneumonia via inhibition of the cytolytic activity of α-hemolysin. J Infect Dis. 2012;206:292–301.CrossRef Qiu JZ, Niu XD, Dong J, et al. Baicalin protects mice from staphylococcus aureus pneumonia via inhibition of the cytolytic activity of α-hemolysin. J Infect Dis. 2012;206:292–301.CrossRef
39.
go back to reference Wan QF, Wang H, Han XB, et al. Baicalin inhibits TLR7/MYD88 signaling pathway activation to suppress lung inflammation in mice infected with influenza A virus. Biomed Reports. 2014;2:437–41.CrossRef Wan QF, Wang H, Han XB, et al. Baicalin inhibits TLR7/MYD88 signaling pathway activation to suppress lung inflammation in mice infected with influenza A virus. Biomed Reports. 2014;2:437–41.CrossRef
Metadata
Title
Baicalin, a component of Scutellaria baicalensis, alleviates anorexia and inhibits skeletal muscle atrophy in experimental cancer cachexia
Authors
Bin Li
Lili Wan
Yan Li
Qi Yu
Pengguo Chen
Run Gan
Quanjun Yang
Yonglong Han
Cheng Guo
Publication date
01-12-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2558-9

Other articles of this Issue 12/2014

Tumor Biology 12/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine